Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1688

1.

Anti-depressant activity of Erythrina variegata bark extract and regulation of monoamine oxidase activities in mice.

Martins J, Brijesh S.

J Ethnopharmacol. 2019 Oct 7:112280. doi: 10.1016/j.jep.2019.112280. [Epub ahead of print]

PMID:
31600560
2.

Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): Study protocol for a randomized controlled trial.

Guan J, Guo Y, Chang P, Gan J, Zhou J, Wang H, Cen Z, Tang Y, Liu Z, Chen P.

Medicine (Baltimore). 2019 Sep;98(39):e17354. doi: 10.1097/MD.0000000000017354.

3.

Serotonin exerts a direct modulatory role on bladder afferent firing in mice.

Konthapakdee N, Grundy L, O'Donnell T, Garcia-Caraballo S, Brierley SM, Grundy D, Daly DM.

J Physiol. 2019 Sep 14. doi: 10.1113/JP278751. [Epub ahead of print]

PMID:
31520534
4.

[Effect of intravenous granisetron combined and acupuncture point injection at PC6(Neiguan) with 0.9% sodium chlorideon postoperative nausea and vomiting after gynecological laparoscopy].

Yu Y, Fan H, Cheng Y, Sun JL.

Zhonghua Yi Xue Za Zhi. 2019 Sep 3;99(33):2606-2610. doi: 10.3760/cma.j.issn.0376-2491.2019.33.010. Chinese.

PMID:
31510721
5.

Simultaneous Determination of Co-administrated Deflazacort, Aprepitant and Granisetron in Dosage Forms and Spiked Human Plasma by RP-HPLC/PAD.

Tantawy MA, Alweshahy S, Elshabasy DA, Youssef NF.

J Chromatogr Sci. 2019 Aug 28. pii: bmz062. doi: 10.1093/chromsci/bmz062. [Epub ahead of print]

PMID:
31504281
6.

Extended release granisetron: Review of pharmacologic considerations and clinical role in the perioperative setting.

Ngo AL, Orhurhu V, Urits I, Delfin EO, Sharma M, Jones MR, Viswanath O, Urman RD.

Saudi J Anaesth. 2019 Jul-Sep;13(3):231-236. doi: 10.4103/sja.SJA_817_18. Review.

7.

Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor.

Basak S, Gicheru Y, Kapoor A, Mayer ML, Filizola M, Chakrapani S.

Nat Commun. 2019 Jul 19;10(1):3225. doi: 10.1038/s41467-019-11142-8.

8.

Comparison of IV granisetron and IV palonosetron on hemodynamics and sensory and motor block after spinal anesthesia with hyperbaric bupivacaine in patients undergoing abdominal hysterectomy.

Choudhary J, Mahajan R, Mahajan A, Gulati S, Mehta A, Nazir R.

J Anaesthesiol Clin Pharmacol. 2019 Apr-Jun;35(2):176-181. doi: 10.4103/joacp.JOACP_334_17.

9.
10.

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.

Iihara H, Shimokawa M, Gomyo T, Fujita Y, Yoshida T, Funaguchi N, Minato K, Kaito D, Osawa T, Yamada M, Hirose C, Suzuki A, Ohno Y.

BMJ Open. 2019 Jul 4;9(7):e028056. doi: 10.1136/bmjopen-2018-028056.

11.

Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan.

Kashiwa M, Matsushita R.

BMC Health Serv Res. 2019 Jul 1;19(1):438. doi: 10.1186/s12913-019-4281-0.

12.

The effect of anti-emetic drugs on rat embryonic heart activity.

Ritchie HE, Huss IB, Webster WS.

Reprod Toxicol. 2019 Aug;87:140-145. doi: 10.1016/j.reprotox.2019.06.002. Epub 2019 Jun 11.

PMID:
31199962
13.
14.

Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.

Schwartzberg LS, Marks SM, Gabrail NY, Geller RB, Kish J.

J Comp Eff Res. 2019 Jul;8(9):657-670. doi: 10.2217/cer-2018-0104. Epub 2019 May 9.

15.

Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study.

Sharafkhah M, Aghakarim Alamdar M, Massoudifar A, Abdolrazaghnejad A, Ebrahimi-Monfared M, Saber R, Mohammadbeigi A.

Int Clin Psychopharmacol. 2019 Sep;34(5):222-233. doi: 10.1097/YIC.0000000000000267.

PMID:
31058716
17.

Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.

Araz M, Karaagac M, Korkmaz L, Koral L, Inci F, Beypinar I, Uysal M, Artac M.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1091-1097. doi: 10.1007/s00280-019-03831-4. Epub 2019 Apr 8.

PMID:
30963213
18.

Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans.

Lang D, Radtke M, Bairlein M.

Chem Res Toxicol. 2019 Jun 17;32(6):1115-1122. doi: 10.1021/acs.chemrestox.8b00413. Epub 2019 Apr 16.

PMID:
30950278
19.

Granisetron reduces the need for uterotonics but not sympathomimetics during cesarean delivery.

Raimann FJ, Baldauf HP, Louwen F, Jennewein L, Fischer D, Zacharowski K, Weber CF.

Int J Gynaecol Obstet. 2019 Jun;145(3):361-366. doi: 10.1002/ijgo.12819. Epub 2019 Apr 15.

PMID:
30932170
20.

[Information Gaps in Package Inserts Cause Insufficient Patient Information on Correct Handling of Transdermal Patches].

Lampert A, Haefeli WE, Seidling HM.

Dtsch Med Wochenschr. 2019 Mar;144(5):e36-e41. doi: 10.1055/a-0722-7419. Epub 2019 Mar 5. German.

PMID:
30836398

Supplemental Content

Loading ...
Support Center